<DOC>
	<DOCNO>NCT01744353</DOCNO>
	<brief_summary>The purpose study test safety , activity best dose FOLFOX-A consist standard chemotherapy drug fluorouracil , leucovorin , oxaliplatin abraxane . Each drug currently use pancreatic cancer . The experimental part study combine drug together FOLFOX-A .</brief_summary>
	<brief_title>BrUOG 278 : FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study</brief_title>
	<detailed_description>More active treatment desperately need pancreatic cancer . The regimen FOLFIRINOX increase survival compare gemcitabine cost increase toxicity . Irinotecan responsible much toxicity FOLFIROX may contribute significantly regimen 's activity . Abraxane new agent pancreatic cancer . This albumin-bound nanoparticle form paclitaxel increase tumor accumulation paclitaxel though bind albumin SPARC pancreatic cancer stroma . The investigator therefore propose pilot study FOLFOX ( fluorouracil , leucovorin oxaliplatin ) combine abraxane establish safety preliminary activity FOLFOX-A . Patients inoperable ( metastatic locally advance ) pancreatic cancer eligible since primary outcome establish safety FOLFOX-A .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Pathologically confirm pancreatic ductal adenocarcinoma . Metastatic locally advance disease . No prior treatment pancreatic cancer Radiographically measurable disease . No major surgery within 4 week start study treatment . Patients must recover side effect major surgery start study treatment . Laparoscopy central venous catheter placement consider major surgery . Patients serious medical risk factor involve major organ system investigator considers unsafe patient receive FOLFOXA Preexisting neuropathy &gt; grade 1 . No prior invasive malignancy within prior two year . However , patient early stage malignancy expect require treatment next 2 year ( early stage , resect breast cancer asymptomatic prostate cancer ) eligible . ECOG performance status 0 1 . Age ≥ 18 year age . Not pregnant nursing . Women child bear potential must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 7 day prior begin treatment . Required Initial Laboratory Values : Neutrophils ≥ 1,500/μl Platelet count ≥ 100,000/μl Creatinine ≤ 1.5 mg/dL creatinine clearance ≥ 60 mL/min Total bilirubin ≤ 1.5 x ULN AST ( SGOT ) &amp; ALT ( SGPT ) ≤ 3.0 x ULN Patients know brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>newly diagnose</keyword>
	<keyword>advanced pancreatic cancer</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>metastatic pancreatic cancer</keyword>
	<keyword>pancreas</keyword>
</DOC>